Founded in 2010, Celnovte Biotechnology has, after over a decade of independent R&D, established a leading position in the R&D, production, and innovation of tumor pathology reagents and instruments. Committed to providing integrated "reagent + instrument" solutions, our products cover routine pathology, immunohistochemistry, molecular pathology, and more. We deliver total pathology laboratory solutions, support the upgrade and renovation of pathology equipment, and empower the national healthcare infrastructure initiative.
Immunohistochemistry (IHC) Staining Instruments
Responding to market demands, Celnovte Biotechnology has successively launched four fully automated IHC staining instruments: the CNT300, CNT320, CNT330, and CNT360 (M1/M2 models). Built on years of independent R&D, these instruments represent domestically developed core technologies with continuous iterative upgrades. They are designed to meet diverse pathology needs and contribute to the advancement of pathology in China.
The CNT360 fully automated IHC stainer, recognized for its outstanding overall performance, has been successfully selected for the 11th batch of the "Excellent Domestic Medical Equipment Product Catalog."
IHC Secondary Antibody Detection Systems
Our independently developed immunostaining reagents have secured national invention patents and obtained international certifications, including CE and FDA approval.
We have innovatively launched a "Mouse & Rabbit Primary Antibody" Simultaneous Amplification System. This system enables signal amplification for both mouse and rabbit primary antibodies simultaneously, effectively resolving issues with poor staining results or difficult-to-stain primary antibody projects and tissues.
"Mouse & Rabbit Primary Antibody" Simultaneous Amplification Detection System:
This system achieves industry-leading amplification levels for mouse-derived primary antibodies, while also providing significant amplification for rabbit-derived primary antibodies. It overcomes the amplification performance differences typically seen between mouse and rabbit antibodies in traditional amplification systems, truly realizing the goal of "one secondary antibody, comprehensive amplification, and ease of use" for the user.
Staining Result Comparison:
IHC Primary Antibodies
Celnovte Biotechnology possesses over 10 years of experience in antibody preparation, utilizing technologies including hybridoma, single B-cell monoclonal antibody platforms, and engineered antibody platforms. We offer 468 types of IHC primary antibodies, fully covering commonly used antibodies in pathological diagnosis. Over 100 antibodies developed on our proprietary technology platforms have undergone rigorous screening and optimization across multiple platforms, all achieving excellent staining performance.
Class III Registered Products
Our HER2 (C1F7), ER (C6H7), PR (C4D10), CD20 (C4A11) antibodies, and HER2 FISH probes have all obtained China's Class III medical device registration certificates. From IHC protein expression to FISH genetic testing, we establish a diagnostic loop with "dual gold standards," ensuring authoritative, compliant, and stable results. Choose our certified products for stronger evidence in the precise diagnosis and treatment of breast cancer and lymphoma.
ADC Companion Diagnostics (CDx)
We are strategically positioning ourselves at the forefront of ADC R&D to define the future with precision diagnostics. With a deep focus on the ADC companion diagnostics (CDx) field, we are committed to providing a full-process, one-stop solution—from the development and performance validation of high-specificity target antibodies to the clinical registration of CDx kits.
Our ADC targets include:
EGFR, FGFR2b, FRa, TROP2, CCR8, CDH17, B7-H3, CD79b, CLDN18.2, B7-H4, MUC1, DLL3, HER3, Nectin-4, PSMA, cMET, MUC16, CTLA4, PDGFRa, CLDN6, TF, and others.
